Cagrilintide

Cagrilintide is Novo Nordisk's long-acting amylin analog, now in multiple Phase 3 trials as a standalone obesity treatment and as half of CagriSema, the company's next-generation weight loss combination that published two landmark NEJM papers in 2025 [1][2]. The standalone Phase 3 program tests whether amylin-pathway activation alone delivers clinically meaningful weight loss without a GLP-1 partner [3][4]. For Novo Nordisk, cagrilintide is both a pipeline extension and an insurance policy for their obesity franchise.

Cagrilintide has never been approved as a standalone drug. Novo Nordisk is running two parallel Phase 3 monotherapy trials: one in 300 adults with overweight or obesity without diabetes (NCT07220642) and one in 330 adults with the same profile plus type 2 diabetes (NCT07220759) [3][4]. Both have completed enrollment and measure relative change in body weight as the primary endpoint. The combination product CagriSema is further along - two NEJM publications in 2025 reported results from REDEFINE 1 (obesity without diabetes) and REDEFINE 2 (obesity with type 2 diabetes) [1][2]. A separate sub-analysis showed CagriSema also reduces blood pressure, a secondary benefit that could strengthen the commercial case [5]. The cardiovascular outcomes trial REDEFINE 3 (NCT05669755) enrolls 7,101 participants with established cardiovascular disease and is testing CagriSema for 3-point MACE - cardiovascular death, non-fatal heart attack, and non-fatal stroke [6]. Novo Nordisk has also completed a Phase 2 in alcohol-related liver disease (NCT06409130, n=270) [7], signaling interest in expanding the amylin platform beyond metabolic indications. No FDA designations have been disclosed for standalone cagrilintide. Readout timing for the monotherapy Phase 3 trials has not been made public, but both have finished recruiting, so data could emerge in late 2026 or 2027.

When you eat a meal, your pancreas does two things at once: it releases insulin to handle blood sugar, and it releases a lesser-known hormone called amylin. Amylin travels to appetite centers in the brainstem and delivers a clear signal - stop eating. It slows stomach emptying so food sits in your gut longer, suppresses glucagon (a hormone that tells your liver to dump stored sugar into the bloodstream), and directly dials down hunger. In type 2 diabetes, amylin secretion from beta cells deteriorates alongside insulin secretion. In obesity, the amylin signaling system appears to lose sensitivity. Cagrilintide is a synthetic version of amylin, chemically modified with a fatty acid chain that makes it bind to albumin in the blood and persist for a full week, compared to natural amylin's half-life of roughly 15 minutes [8]. It activates the same receptors - calcitonin receptor complexes paired with proteins called RAMPs - but with once-weekly dosing. The biological rationale for combining cagrilintide with semaglutide (a GLP-1 receptor agonist) is that amylin and GLP-1 suppress appetite through different but complementary brain circuits. Activating both pathways at once produces more weight loss than either alone, as the REDEFINE trials confirmed [1][2]. The standalone Phase 3 trials now test the harder question: does amylin activation without the GLP-1 component generate enough weight loss to justify a separate product? The prior amylin analog pramlintide (Symlin), approved in 2005 for diabetes, hinted at weight loss but required multiple daily injections and showed modest results [9].

The lead trial for standalone cagrilintide in obesity is NCT07220642, a Phase 3 study enrolling 300 adults with overweight or obesity and no type 2 diabetes, measuring relative change in body weight as the primary endpoint [3]. A mirror trial, NCT07220759, enrolls 330 adults with the same weight criteria plus type 2 diabetes, using the identical primary endpoint [4]. Both are Novo Nordisk-sponsored, have completed enrollment, and follow standard design for obesity programs - likely placebo-controlled with lifestyle intervention in both arms over a 52-to-68-week treatment period. The broader cagrilintide clinical program is extensive. REDEFINE 1 tested CagriSema in adults with obesity and no diabetes; REDEFINE 2 tested it in adults with obesity and type 2 diabetes, both published in the NEJM in 2025 [1][2]. REDEFINE 3 (NCT05669755) is the 7,101-participant cardiovascular outcomes trial testing CagriSema against placebo for MACE, which will determine whether the combination earns a cardioprotective label [6]. A completed Phase 1 (NCT06403761, n=158) examined how CagriSema affects insulin sensitivity using hyperinsulinemic euglycemic clamp, a gold-standard metabolic measurement [10]. And the completed Phase 2 in alcohol-related liver disease (NCT06409130, n=270) used enhanced liver fibrosis score as its primary endpoint [7] - a signal that Novo sees the amylin platform reaching beyond weight management. The standalone trial design is clean but the sample sizes (300 and 330) are modest, suggesting these may be positioned more as label-enabling studies than as definitive commercial evidence.

The model gives this drug a 33% chance of eventually being approved. That estimate starts from the historical approval rate for Phase 3 drugs in this area (about 66%), then adjusts based on ten facts about the trial and its sponsor. On the positive side, the drug has more secondary endpoints than usual and the sponsor has a strong track record of approvals; on the negative side, the trial uses heavier-than-usual blinding and earlier-phase results were weak or limited. The remaining factors fell close to average for this stage and did not shift the estimate much.

Standalone cagrilintide is worth tracking but is not the main event - CagriSema is. The monotherapy Phase 3 trials look designed to give Novo Nordisk regulatory optionality and a patent-protected fallback. They position cagrilintide as a platform molecule that could be combined with future drugs beyond semaglutide, and they provide a treatment option for the GLP-1-intolerant population, which is not small. The data points to watch: standalone Phase 3 topline results, which will reveal whether monotherapy weight loss exceeds the approximately 10-11% seen in Phase 2 when run over a longer treatment period. If it hits 13-15% in the longer trial, the commercial calculus changes. REDEFINE 3 cardiovascular outcomes data will determine whether CagriSema earns a cardioprotective label, a prize that could expand the addressable market by billions. The alcohol-related liver disease signal from the completed Phase 2 (NCT06409130) is a dark horse - if amylin agonism shows antifibrotic effects, that opens a new therapeutic axis [7]. Watch Eli Lilly's eloralintide (LY3841136), which published clinical proof-of-concept data in 2025 [11]. If Lilly builds a serious amylin program, it validates the pathway and intensifies competition simultaneously. Novo Nordisk's GLP-1 franchise generates tens of billions in annual revenue - Wegovy alone reported DKK 74.5 billion (approximately $10.5 billion) in 2024 [12]. Cagrilintide is designed to defend and extend that position. Check back when the standalone Phase 3 data reads out.